Effect of cisplatin treatment on early activation of oncogenes in vivo

Árpád Németh, Zoltán Gyöngyi, Edit Nádasi, Ágoston Ember, Lajos Olasz, Zoltán Nyárády, Jozsef Skapinyecz, I. Ember

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The aim of the study was to monitor the early effect of cytostatics containing platinum on oncogenes in inbred CBA/Ca mice. In human head-neck tumors after treatment with the Cisplatin supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol, further surgeries are often necessary due to regional recurrence. Body weight equivalent amounts of human dose of Cisplatin were administered intraperitoneally to 6-8-week-old, inbred, female CBA/Ca mice. Twenty four 48 and 72 hours after the treatment RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes was examined by dot-blotting in potential target tissues. Significant overexpression of Ha-ras, and p53 genes was measured in the bone marrow. Regarding the expression of Ha-ras gene, a significant increase was also found in the lymph nodes after 48 hours. The p53 expression in the lungs was down-regulated compared to the control group. In the "short-term" in vivo test, 24-hour examination of gene expression and amplification is suitable for detecting the early effects of carcinogenetic exposure. Cisplatin-induced gene expression alterations call attention to its possible role in the development of regional recurrence in patients treated with cisplatin-containing regimens.

Original languageEnglish
Pages (from-to)307-310
Number of pages4
JournalIn Vivo
Volume16
Issue number5
Publication statusPublished - Sep 2002

Fingerprint

Oncogenes
Cisplatin
ras Genes
Chemical activation
Inbred CBA Mouse
Genes
p53 Genes
Gene expression
Gene Expression
Recurrence
Gene Amplification
Bleomycin
Cytostatic Agents
Vincristine
Therapeutics
Platinum
Methotrexate
Surgery
Tumors
Bone

Keywords

  • Biomarkers
  • CBA/Ca mice
  • Cisplatin
  • Gene expression
  • Oral carcinomas
  • Tumor recidives

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Németh, Á., Gyöngyi, Z., Nádasi, E., Ember, Á., Olasz, L., Nyárády, Z., ... Ember, I. (2002). Effect of cisplatin treatment on early activation of oncogenes in vivo. In Vivo, 16(5), 307-310.

Effect of cisplatin treatment on early activation of oncogenes in vivo. / Németh, Árpád; Gyöngyi, Zoltán; Nádasi, Edit; Ember, Ágoston; Olasz, Lajos; Nyárády, Zoltán; Skapinyecz, Jozsef; Ember, I.

In: In Vivo, Vol. 16, No. 5, 09.2002, p. 307-310.

Research output: Contribution to journalArticle

Németh, Á, Gyöngyi, Z, Nádasi, E, Ember, Á, Olasz, L, Nyárády, Z, Skapinyecz, J & Ember, I 2002, 'Effect of cisplatin treatment on early activation of oncogenes in vivo', In Vivo, vol. 16, no. 5, pp. 307-310.
Németh Á, Gyöngyi Z, Nádasi E, Ember Á, Olasz L, Nyárády Z et al. Effect of cisplatin treatment on early activation of oncogenes in vivo. In Vivo. 2002 Sep;16(5):307-310.
Németh, Árpád ; Gyöngyi, Zoltán ; Nádasi, Edit ; Ember, Ágoston ; Olasz, Lajos ; Nyárády, Zoltán ; Skapinyecz, Jozsef ; Ember, I. / Effect of cisplatin treatment on early activation of oncogenes in vivo. In: In Vivo. 2002 ; Vol. 16, No. 5. pp. 307-310.
@article{727dc8721bc14c1fa4bd2c241ca13ea9,
title = "Effect of cisplatin treatment on early activation of oncogenes in vivo",
abstract = "The aim of the study was to monitor the early effect of cytostatics containing platinum on oncogenes in inbred CBA/Ca mice. In human head-neck tumors after treatment with the Cisplatin supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol, further surgeries are often necessary due to regional recurrence. Body weight equivalent amounts of human dose of Cisplatin were administered intraperitoneally to 6-8-week-old, inbred, female CBA/Ca mice. Twenty four 48 and 72 hours after the treatment RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes was examined by dot-blotting in potential target tissues. Significant overexpression of Ha-ras, and p53 genes was measured in the bone marrow. Regarding the expression of Ha-ras gene, a significant increase was also found in the lymph nodes after 48 hours. The p53 expression in the lungs was down-regulated compared to the control group. In the {"}short-term{"} in vivo test, 24-hour examination of gene expression and amplification is suitable for detecting the early effects of carcinogenetic exposure. Cisplatin-induced gene expression alterations call attention to its possible role in the development of regional recurrence in patients treated with cisplatin-containing regimens.",
keywords = "Biomarkers, CBA/Ca mice, Cisplatin, Gene expression, Oral carcinomas, Tumor recidives",
author = "{\'A}rp{\'a}d N{\'e}meth and Zolt{\'a}n Gy{\"o}ngyi and Edit N{\'a}dasi and {\'A}goston Ember and Lajos Olasz and Zolt{\'a}n Ny{\'a}r{\'a}dy and Jozsef Skapinyecz and I. Ember",
year = "2002",
month = "9",
language = "English",
volume = "16",
pages = "307--310",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Effect of cisplatin treatment on early activation of oncogenes in vivo

AU - Németh, Árpád

AU - Gyöngyi, Zoltán

AU - Nádasi, Edit

AU - Ember, Ágoston

AU - Olasz, Lajos

AU - Nyárády, Zoltán

AU - Skapinyecz, Jozsef

AU - Ember, I.

PY - 2002/9

Y1 - 2002/9

N2 - The aim of the study was to monitor the early effect of cytostatics containing platinum on oncogenes in inbred CBA/Ca mice. In human head-neck tumors after treatment with the Cisplatin supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol, further surgeries are often necessary due to regional recurrence. Body weight equivalent amounts of human dose of Cisplatin were administered intraperitoneally to 6-8-week-old, inbred, female CBA/Ca mice. Twenty four 48 and 72 hours after the treatment RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes was examined by dot-blotting in potential target tissues. Significant overexpression of Ha-ras, and p53 genes was measured in the bone marrow. Regarding the expression of Ha-ras gene, a significant increase was also found in the lymph nodes after 48 hours. The p53 expression in the lungs was down-regulated compared to the control group. In the "short-term" in vivo test, 24-hour examination of gene expression and amplification is suitable for detecting the early effects of carcinogenetic exposure. Cisplatin-induced gene expression alterations call attention to its possible role in the development of regional recurrence in patients treated with cisplatin-containing regimens.

AB - The aim of the study was to monitor the early effect of cytostatics containing platinum on oncogenes in inbred CBA/Ca mice. In human head-neck tumors after treatment with the Cisplatin supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol, further surgeries are often necessary due to regional recurrence. Body weight equivalent amounts of human dose of Cisplatin were administered intraperitoneally to 6-8-week-old, inbred, female CBA/Ca mice. Twenty four 48 and 72 hours after the treatment RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes was examined by dot-blotting in potential target tissues. Significant overexpression of Ha-ras, and p53 genes was measured in the bone marrow. Regarding the expression of Ha-ras gene, a significant increase was also found in the lymph nodes after 48 hours. The p53 expression in the lungs was down-regulated compared to the control group. In the "short-term" in vivo test, 24-hour examination of gene expression and amplification is suitable for detecting the early effects of carcinogenetic exposure. Cisplatin-induced gene expression alterations call attention to its possible role in the development of regional recurrence in patients treated with cisplatin-containing regimens.

KW - Biomarkers

KW - CBA/Ca mice

KW - Cisplatin

KW - Gene expression

KW - Oral carcinomas

KW - Tumor recidives

UR - http://www.scopus.com/inward/record.url?scp=1842856853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842856853&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 307

EP - 310

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -